Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.